SPRY FY2025 EPS Forecast Reduced by Cantor Fitzgerald

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) – Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for ARS Pharmaceuticals in a research report issued on Monday, March 24th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings per share of ($1.21) for the year, down from their previous forecast of ($1.02). The consensus estimate for ARS Pharmaceuticals’ current full-year earnings is ($0.55) per share.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its earnings results on Thursday, March 20th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.56. The business had revenue of $86.58 million for the quarter, compared to analysts’ expectations of $15.46 million.

Several other brokerages have also recently issued reports on SPRY. Leerink Partners boosted their price target on shares of ARS Pharmaceuticals from $26.00 to $27.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Scotiabank started coverage on ARS Pharmaceuticals in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $30.00 target price for the company. William Blair restated an “outperform” rating on shares of ARS Pharmaceuticals in a research report on Monday, March 3rd. Raymond James increased their price objective on ARS Pharmaceuticals from $26.00 to $28.00 and gave the stock a “strong-buy” rating in a report on Tuesday, January 14th. Finally, Oppenheimer initiated coverage on shares of ARS Pharmaceuticals in a report on Monday, February 10th. They set an “outperform” rating and a $40.00 target price on the stock. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, ARS Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $31.00.

ARS Pharmaceuticals Stock Up 2.0 %

NASDAQ:SPRY opened at $13.15 on Wednesday. ARS Pharmaceuticals has a twelve month low of $7.55 and a twelve month high of $18.51. The stock has a market cap of $1.28 billion, a P/E ratio of -25.78 and a beta of 1.03. The firm’s fifty day simple moving average is $12.13 and its 200 day simple moving average is $13.07.

Insider Transactions at ARS Pharmaceuticals

In related news, Director Laura Shawver sold 49,600 shares of the company’s stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $11.21, for a total value of $556,016.00. Following the transaction, the director now directly owns 210,346 shares of the company’s stock, valued at approximately $2,357,978.66. This represents a 19.08 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Eric Karas sold 10,000 shares of ARS Pharmaceuticals stock in a transaction on Thursday, March 20th. The stock was sold at an average price of $14.00, for a total value of $140,000.00. Following the completion of the sale, the insider now directly owns 7,696 shares of the company’s stock, valued at approximately $107,744. The trade was a 56.51 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 159,600 shares of company stock valued at $1,866,516. Insiders own 40.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Barclays PLC raised its position in ARS Pharmaceuticals by 189.7% in the 3rd quarter. Barclays PLC now owns 111,666 shares of the company’s stock worth $1,618,000 after buying an additional 73,127 shares during the last quarter. Allspring Global Investments Holdings LLC grew its stake in shares of ARS Pharmaceuticals by 93.1% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 344,171 shares of the company’s stock worth $3,631,000 after acquiring an additional 165,950 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of ARS Pharmaceuticals by 766.1% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 234,537 shares of the company’s stock valued at $3,401,000 after purchasing an additional 207,456 shares during the last quarter. Peregrine Capital Management LLC bought a new position in ARS Pharmaceuticals during the fourth quarter valued at approximately $4,469,000. Finally, State Street Corp boosted its holdings in ARS Pharmaceuticals by 10.4% in the third quarter. State Street Corp now owns 2,049,542 shares of the company’s stock worth $29,718,000 after purchasing an additional 193,321 shares during the last quarter. 68.16% of the stock is owned by institutional investors.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.